Page 495«..1020..494495496497..500510..»

Thailand says XE variant of COVID-19 ‘likely to be mild’ – Khmer Times

Posted: April 6, 2022 at 2:28 am

Thailands Public Health Ministry on Sunday played down concerns raised by the detection of the first case of the XE Covid-19 strain in the country, saying there is no need to panic as it is not believed to result in as many complications as some previous mutations.

The head of the Centre for Medical Genomics (CMG) at Ramathibodi Hospital, which diagnosed the patient found with the strain, said the individual had already made a full recovery.

The rising number of Covid-19 strains only fuels the rapidity of genomic variation as has been evidenced recently by the emergence of Deltacron, a recombinant virus that contains genes from both Delta and Omicron variants, said Dr Supakit Sirilak, director-general of the Department of Medical Sciences (DMS).

In this case, XE is a recombinant virus of two sublineages of the Omicron variant, BA.1 and BA.2, he said, in response to reports about the detection of the first XE case, which was revealed on Saturday by the CMG.

The DMS is performing genomic sequencing on about 500 virus samples a week, he said, adding the DMS will hold a press briefing today to provide more information about the XE case and its broader implications.

The World Health Organization (WHO) had also on Saturday issued a warning over the XE Omicron variant that many in the medical field fear could be the most transmissible yet.

The XE recombinant was first detected in the UK on Jan 19 and less than 600 sequences have been reported and confirmed since, the WHO said.

Wasun Chantratita, the head of the CMG, said they normally receive virus samples for testing about a week after an infection is confirmed, which explains why by the time the results are known, most patients have already nearly recovered.

Anan Jongkaewwattana, an expert with the National Centre for Genetic Engineering and Biotechnology (Biotec), meanwhile, said those who had already been infected with the sub-variant BA.2 of Omicron may already carry some immunity due to the similarities between the pair BA.2. Dont be more afraid of XE than BA.2 as that strain has already been around town, he said.

Considering a rise in number of patients developing severe symptoms when infected with Covid-19 after a fourth booster shot, he said he recommends delaying seeking further appointments for booster shots until a newer generation of the vaccine is available.

Immunity generated by multiple vaccines may even have an adverse effect and lead to more severe inflammation in those who catch the virus after their shots, he said.

For those who already had two rounds of an inactivated type of Covid-19 vaccine, two more booster shots of other types may be needed, while those who had started with two shots of other types of the vaccine may need only one booster shot for now, he said.

The Centre for Covid-19 Situation Administration (CCSA) on Sunday recorded 26,840 new cases and 97 deaths.

In another development, the National Health Security Office (NHSO) said it is preparing for an expected rise in the number of new Covid-19 patients in the coming weeks. The Songkran festival is thought to be a risk factor in leading to an increase in cases.

Priority in terms of both times given by doctors and specialists as well as access to treatment will be given to new elderly patients, particularly those with underlying health conditions that may exacerbate their symptoms, and children, said NHSO secretary-general Dr Jadej Thammatacharees.

Cambodia has been put on alert for the new variant as the fast approaching Khmer New Year celebration which kicks off next week is likely to see an exodus of Cambodians back from Thailand by migrant workers. Bangkokpost/Khmer Times

Read more here:
Thailand says XE variant of COVID-19 'likely to be mild' - Khmer Times

Posted in Genetic Engineering | Comments Off on Thailand says XE variant of COVID-19 ‘likely to be mild’ – Khmer Times

How Obesity Can Change the Immune System and Its Link to Allergic Inflammation – Genetic Engineering & Biotechnology News

Posted: April 6, 2022 at 2:28 am

When mice with atopic dermatitis are treated with drugs that target the immune system, their itchy skin generally heals quickly. However, scientists have now discovered that the same treatment in obese mice makes their skin worse instead. A new study sheds light on how obesity can change the immune system and how clinicians might be able to better treat allergies and asthma in obese people.

The new study is published in the journalNature in a paper titled, Obesity alters pathology and treatment response in inflammatory disease, and led by researchers at Gladstone Institutes, the Salk Institute for Biological Studies, and the University of California, San Francisco (UCSF).

Decades of work have elucidated cytokine signaling and transcriptional pathways that control T-cell differentiation and have led the way to targeted biologic therapies that are effective in a range of autoimmune, allergic, and inflammatory diseases, the researchers wrote. Recent evidence indicates that obesity and metabolic disease can also influence the immune system although the mechanisms and effects on immunotherapy outcomes remain largely unknown. Here, using two models of atopic dermatitis, we show that lean and obese mice mount markedly different immune responses.

Were living in an era when the rate of obesity is increasing around the world, said Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology and a senior author of the study. Changes in diet and body composition can affect the immune system, so we have to think about how diseases that involve the immune system might differ between individuals.

Our findings demonstrate how differences in our individual metabolic states can have a major impact on inflammation, and how available drugs might be able to improve health outcomes, said Ronald Evans, PhD, senior author of the study, and director of Salks Gene Expression Laboratory and the March of Dimes chair in molecular and developmental biology at Salk.

During his graduate studies at Salk and subsequent research in the Marson lab, Sagar Bapat, MD, PhDnow a pathologist and faculty at UCSFwanted to know, at a molecular level, how obesity affected atopic dermatitis. He discovered that when mice were made obese by eating a high-fat diet prior to the induction of dermatitis, they developed more severe disease than lean animals.

What we were expecting to see in the obese mice was just a greater degree of the same kind of inflammation, said Bapat. Instead, we saw a completely different kind of inflammation.

Scientists had considered atopic dermatitis a TH2 disease; that means the TH2 cells are the ones causing the skin inflammation.

In mice with atopic dermatitis, the researchers observed that the TH2 cells were active. In obese mice with the same condition, however, TH17 cells were activated, which meant at a molecular level, atopic dermatitis was completely different in the obese mice.

When Bapat and his colleagues treated obese mice with a drug known to lessen atopic dermatitis, it made the disease significantly worse.

The treatment became a robust anti-treatment, said Bapat. This suggests that you can have identical twins show up to the hospital with the same disease, but if one is obese and one is lean, maybe the same drug wont work on both.

The researchers suspected that dysfunction in a protein called PPAR-gamma might be mediating the link between obesity and inflammation. In 1995, Evans and his team discovered that PPAR-gamma was a master regulator of fat cells and a target of an approved drug for diabetes.

When the scientists treated obese mice with atopic dermatitis with one of these PPAR-gamma activating drugs, called rosiglitazone, the animals skin improved and the molecular profile of their disease switched back from TH17 to TH2 inflammation. Moreover, the drugs aimed at the TH2 inflammation were then, almost as in lean mice, able to improve the obese animals atopic dermatitis.

Essentially, we immunologically de-fattened obese mice without changing their body weight, said Bapat.

More studies are needed but the study demonstrates how obesity causes a switch in inflammation that has consequences for the pathology of allergic disease and the effectiveness of immune therapies that target TH2-associated inflammation.

What wed like to know more about now is exactly how the T-cell switch happens, said senior author Ye Zheng, PhD, an associate professor in the NOMIS Center for Immunobiology and Microbial Pathogenesis at Salk. There are more details here to uncover that could have relevance for a host of diseases related to allergy and asthma.

This is a case where our scientific discovery could have a very safe and quick application to therapy in people, said Evans. Our preclinical findings suggest that these already FDA approved drugs may have a unique co-treatment benefit in certain patients.

Read more from the original source:
How Obesity Can Change the Immune System and Its Link to Allergic Inflammation - Genetic Engineering & Biotechnology News

Posted in Genetic Engineering | Comments Off on How Obesity Can Change the Immune System and Its Link to Allergic Inflammation – Genetic Engineering & Biotechnology News

Synthetic biology’s past, present and future explored in timely new account – Winnipeg Free Press

Posted: April 6, 2022 at 2:27 am

A woman whose body keeps rejecting her fetus after a few months of pregnancy. A man who, certain at 18 that he needs a vasectomy, suddenly finds in his late 40s that he wants children, but his vasectomy reversal fails. Thus opens The Genesis Machine, with the stories of its two authors.

Its an enticing opening to a fascinating book by quantitative futurist Amy Webb and microbiologist Andrew Hessel, but also a bit of a red herring. Hessel and his wife solved their problem through in vitro fertilization, Webb and her husband theirs through genetic testing and ovulation induction agents. Neither author needed synthetic biology, the field that has sprung up around CRISPR, the DNA-editing machine.

The Genesis Machine

Nevertheless, Webb and Hessel skilfully detail the history, endless possibilities and many upsides of synthetic biology. Via in vitro gametogenesis, same-sex couples will soon be able to have babies bearing their own genetic material, without requiring donors. Wheat DNA has already been edited to produce more fibre, tomatoes to require less water and sunlight. Using stem cells, biologists are already developing protein that is, at a molecular level, actual beef. No cows necessary. No cattle blowing their greenhouse gases into the atmosphere.

Synthetic biology has recently had signal success in Modernas development of mRNA COVID-19 vaccines. Despite anti-vaxxer conspiracy theories, these vaccines are even less dangerous than conventional vaccines.

When the pandemic first hit, Dr. Zhang Yongzhens team in Shanghai decoded the COVID-19 genome in 40 hours and, thankfully, published it to GenBank shortly thereafter, paving the road to several vaccines. Nowadays you can buy a sequencing machine for the price of an iPhone. Pharmaceutical companies are developing mRNA vaccines for malaria and other diseases. At the same time, university researchers are working on editing the genetic structure of the mouths of malaria-carrying mosquitos to make them incapable of biting and, thus, of laying their eggs.

Supplied photo

Authors Amy Webb and Andrew Hessel

Other advances, such as plastic trees whose leaves sequester far more C02 than real trees do, may be far less beneficial than claimed, because Webb and Hessel ignore the exorbitant cost of materials and production.

Older stories of synthetic insulin lead into the contemporary adventures of synthetic biology entrepreneur Craig Venter. Particularly interesting is the account of He Jiankui who, without getting Chinese governmental permission, edited a pair of human twin embryos (hoping to make them immune to AIDS), leading to live births. In 2019, he was sentenced to three years in prison.

Mark Teske / The Associated Press files

Members of the surgical team perform the transplant of a pig heart into patient David Bennett in Baltimore, MD in January 2022. Bennett died in early March.

Despite how the authors baby quests rig the deck emotionally in favour of synthetic biology, the late-arriving Nine Risks chapter offers readers a choice of nightmares. Worried about deepfakes worming their way into the public record and falsifying it? How about augmented viruses leaving the lab and worming their way into your body?

Or how about a near future in which the Haves all have enough genetic enhancements to make the Have-nots nostalgic for their present poverty? Upgrade your children before birth! Certainly, it makes sense to edit out sickle-cell anemia, but it would take a very self-controlled genie not to agree to splice superior looks, athletic ability and intelligence into a customers childrens DNA. Chinas BGI group is already touting IQ boosts.

The EU and a number of countries have legislated against germline engineering, but that was before CRISPR, and that number doesnt include the synthetic biology leaders: China and the U.S. Harvards George Church, who wants to create a mostly woolly mammoth by splicing preserved mammoth DNA with Asian elephants, has also declared an interest in splicing Neanderthal DNA into contemporary humans, and perhaps cloning a Neanderthal. But we really have no idea what will happen when genetically engineered organisms outcross with other organisms in the wild, also known as the world.

Towards the end of The Genesis Machine, Webb and Hessel present some futuristic scenarios: for example, the pamphlet Creating Your Child with Wellspring. Such flourishes might work well for business visioning retreats, but the results in print are weak. Webb and Hessel would be better off staying with the science and leaving fictionalizations of synthetic biology to Richard Powers Generosity (2009) or Margaret Atwoods MaddAddam trilogy (2003-13).

Too recent to have made it into The Genesis Machine is the attempt at the University of Maryland Medical Center to implant a gene-edited pig heart into a human, but Webb and Hessel do mention that Chinese scientists are developing super-pigs that are more virus-resistant, stronger and quicker to mature than the present models. Are we closing in on Atwoods 2003 fictional pigoons pigs spliced with human neocortical tissue?

Life is becoming programmable, say Webb and Hessel. Imagine a synthetic biology app store

Reinhold Kramer is a Brandon University English professor. His most recent book is Are We Postmodern Yet? And Were We Ever?

If you value coverage of Manitobas arts scene, help us do more.Your contribution of $10, $25 or more will allow the Free Press to deepen our reporting on theatre, dance, music and galleries while also ensuring the broadest possible audience can access our arts journalism.BECOME AN ARTS JOURNALISM SUPPORTERClick here to learn more about the project.

More:
Synthetic biology's past, present and future explored in timely new account - Winnipeg Free Press

Posted in Maryland Stem Cells | Comments Off on Synthetic biology’s past, present and future explored in timely new account – Winnipeg Free Press

Identifying Missing Links – and Why Certain Drugs Don’t Work – in Alzhiemer’s – BioSpace

Posted: April 6, 2022 at 2:26 am

Before the U.S. Food and Drug Administrations controversial approval of Biogens Aduhelm (aducanumab) for Alzheimers disease in June 2021, there were well over 200 failed clinical trials in the last twenty years for drugs to treat the disease. Part of the drugs controversy is the alleged negligible improvement in Alzheimers symptoms. At the highest doses, which can be risky, Aduhelm appears to slow the progression of the disease in patients if caught early enough.

Aducanumab is an antibody that clears beta-amyloid in the brain, one of two proteins that accumulate abnormally in the disease. Although beta-amyloid is associated with the disease, its not the only factor, and researchers are making progress on understanding Alzheimer's better and taking new approaches. Heres a look.

Screening Approach to Why Alzheimers Drugs Fail

A team at the University of California, San Diegodeveloped a drug screening method to help determine why Alzheimers drugs fail. The system analyzes disease mechanisms in human neurons. They published their research in Alzheimers & Dementia. The researchers note that sometimes drugs that clear amyloid dont improve the disease but make it worse. With that as the focus, their drug screening method evaluates what endotypes, or disease mechanisms, are modified in the patients neurons from the treatment. They note that although amyloid plaque formation is one endotype, others should be targeted, including differentiation of neurons to an early non-neuron state, neuronal gene suppression and loss of synaptic connection.

The key here is that we are using the endotypes that we discovered to see how current drugs fail, senior author Shankar Subramaniam, Ph.D., said. When drugs interact with human neurons, what endotypes do the drugs fix and what endotypes do they not fix in the process?

Their technique requires taking human-induced pluripotent stem cells derived from patients with familial Alzheimers disease and transforming them into neurons. They then treat these cells with drugs and leverage genetic sequencing to determine what endotypes change pre-and post-treatment. They also do the same on neurons derived from healthy people.

In a test of two experimental Alzheimers drugs targeting amyloid, the researchers found the drugs only improved some endotypes, such as the formation of amyloid plaques, partly fixing some, while not fixing others.

What we are seeing is that fixing amyloid plaque formation does not reverse the disease in any way, Subramaniam said. It turns out that this endotype is way downstream, so it is too late. Once neurons de-differentiate into non-neurons, they lose their synaptic connections, which leads to loss of memory and cognition and as a consequence, dementia.

Targeting Alzheimers Earlier in the Process

Although amyloid and a second protein, tau, are linked to Alzheimers, with amyloid generally occurring earlier and tau later in the disease, some researchers are focused earlier. Qin Wang, MD, Ph.D., with the new Alzheimers Therapeutics Discovery program at the Medical College of Georgia, described amyloid and tau as like a gun in the brain: beta amyloid is the trigger and tau is the bullet. Wang is looking at why and how they interact.

Theres a missing link there, Wang stated.

Earlier in Alzheimers, a group of neurons in a part of the brain called the locus coeruleus seem to die first. Those nerves interact with norepinephrine, a neurotransmitter. Norepinephrine is involved in various processes, including fight or flight, arousal, attention and memory. They have connections throughout the brain and, Wang said, seem to be hypersensitive to amyloid beta and tau.

These cells have a special receptor that can both release, and are involved in receiving norepinephrine. Once turned on, the receptor controls the protein that creates beta amyloid. But once beta amyloid is formed, it can attach to the same receptor in a different location and begin creating more beta amyloid in what Wang describes as a vicious cycle.

This is very important for the initial seeding of the (deposits) in the brain, Wang said.

Wang noted that drugs that target amyloid remove about 60% at best, which isnt nearly enough. Very little beta amyloid is needed to feed the cycle, with even 1% still sufficiently activates this detrimental pathway.

So Wang and her team are evaluating drugs that can prevent that cycle. Two are already on the market. One of them is an approved antidepressant, Idazoxan. Another is a blood pressure medication called clonidine that also activates the particular receptor in the brain.

Hopefully in humans, if we can block those receptors, we will see the oppositive effect, Wang said. We can see an improvement in their cognitive function.

NeuroNascents Neuron Regeneration Drug

NeuroNascent reported data from a Phase I trial of NNI-362 in Alzheimers disease. The drug demonstrated favorable safety and a significant decrease in a biomarker for Alzheimers disease. The drug appears to produce new neurons to replace lost neurons or improve their numbers in aging patients or neurodegenerative diseases, such as Alzheimers.

The drug is taken orally and data showed it to be well tolerated in healthy aged people after single and multiple daily dosing. Using a new test to detective Alzheimers biomarkers in blood plasma, the drug also significantly decreased p-tau181 levels compared to pre-treatment levels.

This exciting early data, demonstrating our novel allosteric oral therapy, NNI-362, can normalize the plasma p-tau181 a biomarker correlated with Alzheimers disease brain pathology and progression, supporting the need to further test NNI-362 in long-term trials, Judith Kelleher-Andersson, Ph.D., founder and chief executive officer of Neuronascent, said. Running of a Phase II trial in mild to moderate Alzheimers disease patients could assess longer-term amelioration of p-tau181 levels and to determine if this intervention could consequently improve quality of life for patient and caregiver.

Read the rest here:
Identifying Missing Links - and Why Certain Drugs Don't Work - in Alzhiemer's - BioSpace

Posted in Georgia Stem Cells | Comments Off on Identifying Missing Links – and Why Certain Drugs Don’t Work – in Alzhiemer’s – BioSpace

Global Placental Stem Cell Collection and Storage Market is Key Driver for the Industry with forecast to 2029 | Cordlife, Cryo-Cell, Stemcyte, Viacord…

Posted: April 6, 2022 at 2:25 am

A market study Global examines the performance of the Placental Stem Cell Collection and Storage market 2022. It encloses an in-depth analysis of the Placental Stem Cell Collection and Storage market state and the competitive landscape globally. The Global Placental Stem Cell Collection and Storage Market can be obtained through the market details such as growth drivers, latest developments, Placental Stem Cell Collection and Storage market business strategies, regional study, and future market status. The report also covers information including Placental Stem Cell Collection and Storage industry latest opportunities and challenges along with the historical and Placental Stem Cell Collection and Storage market future trends. It focuses on the Placental Stem Cell Collection and Storage market dynamics that is constantly changing due to the technological advancements and socio-economic status.

Get free copy of the Placental Stem Cell Collection and Storage market report 2022: https://calibreresearch.com/report/global-placental-stem-cell-collection-storage-market-170974#request-sample

Recent market study Placental Stem Cell Collection and Storage Market analyses the crucial factors of the Placental Stem Cell Collection and Storage market based on present industry situations, market demands, business strategies adopted by Placental Stem Cell Collection and Storage market players and their growth scenario. This report isolates the Placental Stem Cell Collection and Storage market based on the key players, Type, Application and Regions. First of all, Placental Stem Cell Collection and Storage market report will offer deep knowledge of company profile, its basic products and specification, generated revenue, production cost, whom to contact. The report covers forecast and analysis of Placental Stem Cell Collection and Storage market on global and regional level.

COVID-19 Impact Analysis:

In this report, the pre- and post-COVID impact on the market growth and development is well depicted for better understanding of the Placental Stem Cell Collection and Storage Market based on the financial and industrial analysis. The COVID epidemic has affected a number of Placental Stem Cell Collection and Storage Market is no challenge. However, the dominating players of the Global Placental Stem Cell Collection and Storage Market are adamant to adopt new strategies and look for new funding resources to overcome the rising obstacles in the market growth.

Placental Stem Cell Collection and Storage market:AmericordCryobankChina Cord Blood CorporationCelularityLifebankUSAAmericord RegistryReeLabsPluristem TherapeuticsPSTIOcata TherapeuticsMesoblast LimitedCaladrius BiosciencesCBR Systems, Inc.CordlifeCryo-CellStemcyteViacordSmart Cells International Ltd.Cryoviva IndiaCells4LifeH&B Group

Placental Stem Cell Collection and StorageHave Any Query Of Placental Stem Cell Collection and Storage Industry Report 2022: https://calibreresearch.com/report/global-placental-stem-cell-collection-storage-market-170974#inquiry-for-buying

Placental Subtopotent Stem CellsPlacental Hematopoietic Stem CellsPlacental Mesenchymal Stem Cells (MSC)Placental Maternal Pluripotent Stem Cells

Placental Stem Cell Collection and Storage

Cell TherapyBeauty ProductsOther

North America Placental Stem Cell Collection and Storage Market(United States, North American country and Mexico),Europe Market(Germany, Placental Stem Cell Collection and Storage France Market, UK, Russia and Italy),Asia-Pacific market (China, Placental Stem Cell Collection and Storage Japan and Korea market, Asian nation and Southeast Asia),South America Placental Stem Cell Collection and Storage Regions inludes(Brazil, Argentina, Republic of Colombia etc.),Placental Stem Cell Collection and Storage Africa (Saudi Arabian Peninsula, UAE, Egypt, Nigeria and South Africa)

The Placental Stem Cell Collection and Storage report provides the past, present and future Placental Stem Cell Collection and Storage industry Size, trends and the forecast information related to the expected Placental Stem Cell Collection and Storage sales revenue, growth, Placental Stem Cell Collection and Storage demand and supply scenario. Furthermore, the opportunities and the threats to the development of Placental Stem Cell Collection and Storage market forecast period from 2022 to 2029.

Get Complete Report for Better Understanding : https://calibreresearch.com/report/global-placental-stem-cell-collection-storage-market-170974

Further, the Placental Stem Cell Collection and Storage report gives information on the company profile, market share and contact details along with value chain analysis of Placental Stem Cell Collection and Storage industry, Placental Stem Cell Collection and Storage industry rules and methodologies, circumstances driving the growth of the Placental Stem Cell Collection and Storage market and compulsion blocking the growth. Placental Stem Cell Collection and Storage Market development scope and various business strategies are also mentioned in this report.

Read more:
Global Placental Stem Cell Collection and Storage Market is Key Driver for the Industry with forecast to 2029 | Cordlife, Cryo-Cell, Stemcyte, Viacord...

Posted in New Mexico Stem Cells | Comments Off on Global Placental Stem Cell Collection and Storage Market is Key Driver for the Industry with forecast to 2029 | Cordlife, Cryo-Cell, Stemcyte, Viacord…

FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism – Pharmacy Times

Posted: April 6, 2022 at 2:23 am

Estosterone undecanoate (Tlando; Antares Pharma, Inc) is indicated as testosterone replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone in adult patients.

The FDA has approved the oral drug estosterone undecanoate (Tlando; Antares Pharma, Inc) for testosterone replacement therapy (TRT) for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult patients.

The FDA approval of Tlando brings to market an oral formulation of testosterone that we believe will prove beneficial to physicians and their patients. We have recently expanded our commercial organization to 108 sales representatives and expect to leverage our relationships with urologists and endocrinologists to drive adoption of Tlando, said Robert F. Apple, president and chief executive officer of Antares Pharma, in a press release. This approval also reinforces the opportunity for Antares to continue to drive share gains in the TRT market with both Tlando and Xyosted and support our future growth with an expanded commercial portfolio. We look forward to launching Tlando commercially, which will provide a complementary treatment option to patients and clinicians in the second quarter of this year.

Male hypogonadism is an endocrine disorder in which the body is unable to produce enough testosterone. The condition is estimated to affect approximately 35% of men 45 years of age and older, as well as 30% to 50% of men with obesity or type 2 diabetes.

Tlandois indicated for TRT in adult males with conditions such as primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). The safety and efficacy of Tlandohas not been established in males under 18 years of age.

Antares Pharma said it will seek to launch Tlandoin the second quarter of 2022 to provide a complementary treatment option for patients and clinicians

We believe Tlandos oral formulation and convenient dosing, which requires no titration, differentiates it from other treatment options. As we prepare for the commercial launch, we look forward to our sales representatives detailing a differentiated portfolio of products consisting of Xyosted, Tlando and Nocdurna that will continue to deliver solutions for improved patient care, said Joe Renda, senior vice president, Commercial of Antares Pharma, in a press release.

Reference

Antares Pharma Announces FDA Approval Of TLANDO, an Oral Treatment for Testosterone Replacement Therapy Commercial launch expected in 2Q 2022. Antares Pharma. [news release]. March 29, 2022. https://www.biospace.com/article/releases/antares-pharma-announces-fda-approval-of-tlando-an-oral-treatment-for-testosterone-replacement-therapycommercial-launch-expected-in-2q-2022/

Read this article:
FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism - Pharmacy Times

Posted in Testosterone Replacement Therapy | Comments Off on FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism – Pharmacy Times

About the Advanced Age Management Medina Testosterone Replacement Therapy in Medina, OH – Digital Journal

Posted: April 6, 2022 at 2:23 am

Medina, OH: The safe and effective hormone therapy at Advanced Age Management targets people with various health issues, including weight gain, tiredness, declining sex drive, and depressed mood. For men over 35 years, these health problems could result from low testosterone levels and other hormonal issues. That is why the trt center is happy to work with all symptomatic patients. The wellness center for men is well-equipped to offer Hypothyroidism Therapy, Hormone Replacement Treatment, Erectile Dysfunction Treatment, and Low T Symptoms. Other treatments offered by Advanced Age Management are Testosterone Replacement Therapy and Growth Hormone Releasing and Medical Peptide Therapy.

For over 15 years, Advanced Age Management has served patients from varied backgrounds, including professional athletes. The advanced treatment facility for men is owned and managed by John Kocka M.D., a board-certified physician and age management specialist. Dr. Kocka is board-certified in Age Management from the American Academy of Anti Aging, Age Management Medical Group and physician-certified by the Cenegenics Medical Institute. He is a member of the International Hormone Society, International Society for the Study of the Aging Male and the American College of Sports Medicine. He is a trusted authority in testosterone replacement therapy.

Hormone Replacement Therapy (HRT) is a process of replenishing naturally produced hormones among men. The process usually happens when men age and may lead to increased pain and aches, insomnia, sleep disturbance, and slower metabolism, which often leads to increased body fat and other health complications. The pros of choosing Advanced Age Management include an opportunity to work with a leading doctor, access to comprehensive and tailored treatment solutions, and ongoing support from in-house physicians.

The HRT treatment for men plays a vital role in revitalizing sex drive, building muscle mass, and promoting the production of red blood cells. For men with low testosterone levels, the treatment can go a long way to promote vitality, health, and enhance the quality of life. Dr. Kocka begins treatment by creating a custom treatment solution. Treatments such as medina testosterone replacement therapy are supplemented by healthier habits, such as exercise, improved diet, and quality sleep.

Another critical treatment offered by Advanced Age Management is Vitamin B12 and other Amino Acid Treatments. The cost of treatment varies depending on the type of treatment and personalized medical treatment plans. Patient reviews posted on the website paint a picture of an advanced treatment facility that is highly recommended for its friendly and knowledgeable staff and excellent treatment facilities.

To get in touch with the treatment experts at Advanced Age Management, call 216.471.8220, or visit them at 1188 Medina Rd R18, Medina, OH, 44256. The clinic is keen to address health concerns and improve quality of life. They operate Monday to Friday at different hours, between 8:00 am to 5:30 pm.

Media Contact

Company NameAdvanced Age ManagementContact NameJohn Kocka, M.D.Phone216.471.8220Address1188 Medina Rd R18CityMedinaStateOHPostal Code44256CountryUnited StatesWebsitehttps://www.lowtohio.com/

Go here to read the rest:
About the Advanced Age Management Medina Testosterone Replacement Therapy in Medina, OH - Digital Journal

Posted in Testosterone Replacement Therapy | Comments Off on About the Advanced Age Management Medina Testosterone Replacement Therapy in Medina, OH – Digital Journal

Northeast Integrative Medicine Conference to Showcase Expert-Speaker Panel at McAuliffe-Shepard Discovery Center in Concord, NH on May 13, 2022 – PR…

Posted: April 6, 2022 at 2:21 am

Concord, NH - Friday, May 13, 2022

Concord, NH (PRWEB) April 04, 2022

The Northeast Integrative Medicine Conference will take place in-person at the McAuliffe-Shepard Discovery Center in Concord, New Hampshire from 8:30am to 4:30pm, on Friday, May 13, 2022.

Sponsored by Yunieska Krug, founder of Mindful Healing Matters, LLC, and Christine DiStefano, founder of Juniper Spiritual Healing, LLC, in partnership with the Southern New Hampshire Area Health Education Center, this Spring symposium will feature an expert-speaker panel composed of eight distinguished and credentialed New-England-based professionals who will present on a multitude of holistic, evidenced-based practices and applications, for integrative-medicinal modalities.

I am so incredibly excited to gather with such phenomenal colleagues to provide the local community with an educational conference that combines traditional medical knowledge with modern research on holistic alternatives, said Yunieska Krug, event sponsor and founder of Mindful Healing Matters, LLC. There has been an increased interest in these topics among healthcare workers. So, for me, this event is all about community and accessibility its unprecedented in terms of the value it provides in breadth and depth of topics, as well as with such prestigious professional speakers. Amazing opportunity!

This in-person conference will showcase the following expert-speaker panel:

Yunieska Krug, MSW, LICSW, MLADCKrug is a Licensed Independent Clinical Social Worker in Massachusetts and New Hampshire. She is also licensed as a Masters Level Alcohol and Drug Abuse Counselor in New Hampshire. She holds certifications in Cognitive Behavioral Therapy, Dialectal Behavioral Therapy, and Mental Health with aging populations.

Susan Wilkes, Certified Music Practitioner/Therapeutic MusicianWith a Music Teaching Career that spans more than three decades in Vermont and New Hampshire, Wilkes earned a BA in Music Education from Westfield State College, and Master of Music Degree in Conducting at UMass Lowell, as well as a Masters Degree in Health Arts and Sciences at Goddard College.

Dr. Rob Spencer, MDDr. Spencer has been involved with end-of-life care since 1981. In 2013, he was appointed by the Governor of New Hampshire to serve on a legislative commission to study Palliative Care. He completed his undergraduate studies in Psychology from Yale College, and graduated from Yale School of Medicine in 1990. Since 1996, he has been a Physician, Medical Director, Consultant and Teacher. Inspired by caring for patients at the end of life, Dr. Spencer has adapted tools and techniques used in Hospice and Palliative Care for the benefit of people who are alive and well.

Zoe Gillis, MA, MFTGillis is a Licensed Marriage and Family Therapist. She is trained in the Trauma-Informed Treatment EMDR, and is Certified by the Greater Good Science Center as a Mindfulness and Meditation Teacher. Additionally, she is a Certified Wilderness First-Responder, and specializes in group facilitation. With over 10 years experience in Psychotherapy, and 15 years experience as a Wilderness Guide, she offers a unique perspective and breadth of knowledge.

Emily Marsh, MSN, RN, ONCMarsh received her Associate of Science in Nursing from New Hampshire Technical Institute in 2007, where she has also been an adjunct professor since 2014. She has been in the role of Orthopedic Nurse Educator at Concord Hospital since 2011. She earned her Master of Science in Nursing from Walden University in 2012. She also obtained her Orthopedic Nurse Certification from the Orthopedic Nurse Certification Board in 2012. Marsh is currently the co-chair of the Holistic Healing Council at Concord Hospital. She has presented at various professional industry conferences and has published research which has advanced the field of nursing.

Donna Millette, BSIEMillette is a Performance Improvement Project Manager at Lahey Health in Burlington, Massachusetts. In 2011, She joined Concord Hospital as Director of Lean Operations. In 2016, she took on the role of Director of Process Analytics. She is a founding member of the New Hampshire Lean Network (NHLN).

Lisa Kardos, MS, OTR/L, RYTKardos is an Occupational Therapist and Yoga Teacher who has been in the field of medicine for 15 years, working with the adolescent, adult and older adult population. She specializes in Geriatric Habilitation, Behavioral Health, Mental Health, Mindfulness, DBT, Holistic Health, Compassion Fatigue Prevention, Yoga, Sensory Regulation, Trauma Informed Care, Trauma Sensitive Therapy and Crisis Prevention.

Christine DiStefano, BA, SUTDiStefano received a BA from Framingham State University in 2009. She went on to successfully lead a decade-long, award-winning career in Marketing and Advertising. As of 2022, she became the proud owner of Juniper Spiritual Healing, LLC. Parallel to managing her small business, DiStefano is also working in Substance Use Treatment as a Residential Instructor.

We are just beyond thrilled to showcase this incredibly qualified panel of speakers who will be presenting on topics like the power of therapeutic music in medicine, the role of aromatherapy in medicine, trauma-informed yoga and so much more, said Christine DiStefano, event sponsor and founder of Juniper Spiritual Healing, LLC. This is an amazing educational opportunity for local healthcare professionals interested in integrating the newest research and holistic applications into their current clinical approach. Im excited for the vibe, especially being in-person its going to be fantastic!

The Northeast Integrative Medicine Conference is a limited-ticket event which provides a uniquely intimate opportunity to engage with medical experts and health innovators. This compact one-day symposium includes lunch and giveaways.

Registration for the 2022 Northeast Integrative Medicine Conference is now open.Register today to secure your seat, tickets are limited!

Continuing Education:Southern New Hampshire Area Health Education Center is an approved provider with distinction of nursing continuing professional development by the Northeast Multistate Division Education Unit, an accredited approver by the American Nurses Credentialing Centers Commission on Accreditation. 5.25 Contact Hours Activity Number: 1439

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Southern NH AHEC and Mindful Healing Matters, LLC. The Southern NH AHEC is accredited by the NH Medical Society to provide continuing medical education for physicians. Southern New Hampshire Area Health Education Center designates this live activity for a maximum of 5.25 AMA PRA category 1 Credit (s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

5.25 CEUs pending approval from NASW NH.The LADC Application for continuing education is pending approval.For other professionals: 5.25 professional hours of continuing education.

Read the original here:
Northeast Integrative Medicine Conference to Showcase Expert-Speaker Panel at McAuliffe-Shepard Discovery Center in Concord, NH on May 13, 2022 - PR...

Posted in Integrative Medicine | Comments Off on Northeast Integrative Medicine Conference to Showcase Expert-Speaker Panel at McAuliffe-Shepard Discovery Center in Concord, NH on May 13, 2022 – PR…

8 Ways To Improve Brain Function As We Age – TravelAwaits

Posted: April 6, 2022 at 2:21 am

Thanks to advances in medicine and integrative care focusing on lifestyle changes, people are living longer and better. The new standard is not just longevity but also vitality, which is why integrative lifestyle medicine is so important. It focuses on helping people live their best lives, doing more of what they love. While we tend to focus a great deal on physical capabilities, maintaining and improving brain function is a big piece of the puzzle.

What if I told you there are simple little things you can do right now that will help protect your brain and improve memory? After 20 years of blending traditional medicine with functional medicine in my integrative practice, Ive seen enough proof that the following recommendations can make a big difference. But, spoiler alert, the two most important things you can do are stay active and exercise and eat healthfully.

Contrary to the standard American diet, our bodies were not designed to consume large amounts of simple sugars and carbohydrates. When it comes to health, food matters. And if youre serious about feeling better, theres no way around a diet reset.

Study after study confirms that an excess of sugar in the blood is bad for the brain. In fact, Alzheimers Dementia is also known as Type 3 diabetes, suggesting the neurodegenerative effects of hyperglycemia and insulin resistance on the brain. One of my favorite books that addresses this is The Grain Brain by David Perlmutter, MD.

Simple steps like limiting white and processed foods such as breads, pastas, sugar, and white rice as much as possible can help get these under control. I always tell my patients to decrease consumption of what comes in a box or bag. Be sure to include healthy fats in your diet every day with things like avocado, nuts, and seeds. Choose leaner meats like chicken, fish, and turkey. And dont forget to eat your veggies! Work toward to four servings of vegetables each day.

Salmon, anchovies, mackerel, sardines, and herring (easily remembered with the acronym SMASH) are rich in omega-3 fatty acids. Omega-3s are essential for improved brain function. SMASH fish also boast lower deposits of heavy metals such as mercury, which are toxins that can adversely affect brain function. Always choose wild-caught fish. Farmed fish are given grains and not allowed to swim or be as active as wild-caught fish.

My favorite type of intermittent fasting is whats called time-restricted fasting. This may look different for each person, but I typically advise my patients to stop eating after dinner and fast for 14 hours. If you finish dinner at 7 p.m., dont eat again until 9 the following morning. This 14-hour overnight fast allows the body to use up all the glucose it has and then metabolically switch energy resources to ketones. This process has been associated with improving measurable cognitive markers including psychomotor speed, memory, and learning skills.

Fasting also gives your body time for something called autophagy. Autophagy is like housekeeping for your cells. Its the process by which the body destroys and recycles old cells so that it can create new, healthier cells. This process is especially important for improving brain function.

Any form of exercise is great for brain health whether it is hiking, biking, walking, or running. Just keep moving! But if youre looking for a specific workout to improve your memory, try HIIT (high-intensity interval training)! If you are new to HIIT, YouTube has a wealth of HIIT videos for beginners. Another great option is the free 7 Minute Workout APP which works great when on vacation or traveling. You can do most HIIT workouts in your hotel room or on the beach with a few simple modifications.

Bonus! Download the free Lumosity APP and exercise your brain for 10 minutes a day!

Youve heard it before: Get 7 to 8 hours of sleep every night! There are so many benefits of a good nights sleep, but especially for the brain. Good quality sleep gives your brain time to clear out toxins and organize information. Youll wake up with less brain fog, more creativity, better ability to regulate your appetite, and more!

If you struggle with sleep, start by disciplining yourself to go to bed and wake up each day (seven days each week!) at the same time. This helps your bodys circadian rhythm stay in check.

Red wine, dark chocolate (just watch the sugar!), berries, coffee, kale, matcha green tea, extra virgin olive oil, walnuts, parsley, red onions, soy, and turmeric all have something in common: sirtuins. Sirtuins are proteins that regulate aging by decreasing inflammation and promoting cellular health. They also help with sleep by balancing our circadian clocks and improving metabolism through mitochondrial production.

If youve been looking for that excuse to get a sauna, youre welcome! Exposing your body to heat helps you get rid of heavy metals and other toxins like BPA. If you dont have access to a sauna, anything that increases your body temperature is helpful including exercise.

In a perfect world, we would get all our nutrients from food. But since that is rarely the case, I always recommend the following supplements to my patients who are especially concerned about brain health.

Weve covered a lot of ground here and some ideas are a little easier to implement than others, but the health trade-off is great. If you are ready to make some positive changes but still struggling with where to begin, find a functional medicine doctor or a good dietician who can work with you and make more specific daily dietary recommendations. Also, before you add a new supplement or begin any exercise routine, talk to your doctor to make sure its safe for you especially if you have been diagnosed with a chronic disease like diabetes or heart disease.

The information found on TravelAwaits is intended for informational and educational purposes only and not for the purpose of rendering medical advice. Always seek the advice of a physician or other qualified healthcare provider with any questions regarding a medical condition.

For more inspiration, consider

Follow this link:
8 Ways To Improve Brain Function As We Age - TravelAwaits

Posted in Integrative Medicine | Comments Off on 8 Ways To Improve Brain Function As We Age – TravelAwaits

Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy – GlobeNewswire

Posted: April 6, 2022 at 2:21 am

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently published a study in Nature Communications using network modeling to identify novel targets for treating patients with early-stage invasive lung adenocarcinoma.

This new paper demonstrates how the synergism of in silico, in vitro, and in vivo technologies can accelerate the drug discovery process, saidEric Schadt, PhD, Founder and Chief Executive Officer of Sema4 and an author on the paper. By performing an integrative network analysis of early-stage lung adenocarcinoma, together with our partners at Icahn Mount Sinai, we were able to identify a gene expression signature capable of stratifying patients for treatment and a potential novel therapeutic for these patients.

The approaches to diagnosing and treating early-stage lung adenocarcinoma are evolving and are based upon advances in understanding the biology and clinical activities of these tumors, said senior author Charles Powell, MD, MBA, Janice and Coleman Rabin Professor of Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine at Icahn Mount Sinai. Our work using novel network approaches in collaboration with Sema4 to identify signatures of invasiveness and to identify drugs that can intercept progression of these cancers should contribute to advancing the understanding and outcomes for this cancer.

Lung adenocarcinoma is the most common lung cancer in the United States. Because of its often aggressive nature, early diagnosis is critical to improving survival. The new study disentangles the molecular mechanisms underlying tumor invasion in early-stage lung adenocarcinoma to improve patients diagnosis, prognosis, and treatment.

Sema4s advanced predictive modeling and data science expertise uniquely position us to deliver value to and accelerate discovery for collaborators in the biopharma, healthcare, and research worlds, said Gustavo Stolovitzky, PhD, Chief Science Officer at Sema4. Through this collaboration, we again proved the value of our integrative network modeling by uncovering a novel way to stratify early-stage lung adenocarcinomas into indolent and aggressive forms and positing a potential therapeutic to help patients with the aggressive type. Dependent upon clinical validation, genomic testing for the invasiveness signature could one day be incorporated into our Sema4 Signal portfolio of precision oncology solutions to help guide treatment decisions for patients with aggressive early-stage lung adenocarcinoma.

In the collaborative study that builds upon the NIH-funded lung cancer research program in Dr. Powells laboratory, researchers from Icahn Mount Sinai collected early-stage lung adenocarcinoma tumor samples and sequenced their RNA. Sema4 then analyzed the network of gene-gene interactions based on this sequencing data, resulting in the identification of a gene expression signaturethat can distinguish between invasive and noninvasive tumors.

When we annotated the gene signature, we uncovered an enrichment for genes associated with tumor invasion-related functions, said Jun Zhu, PhD, Head of Data Sciences at Sema4 and Professor of Genetics & Genomic Sciences at Icahn Mount Sinai (Dr. Zhu was the joint senior author on the paper). We then analyzed retrospective patient data and defined a numerical index based on gene expression in the patients, which we called the 'invasiveness score. We found that this invasiveness score is strongly associated with survival in multiple independent cohorts, confirming its prognostic significance.

Researchers at Icahn Mount Sinai showed that the invasiveness score is also strongly associated with invasiveness in cancer cell lines and validated it in a mouse model of early-stage lung adenocarcinoma. The integrative network analysis identified aurora kinases as master regulators of this invasiveness and suggested that they are good targets for treating early-stage lung adenocarcinoma. Aurora kinases have known roles in tumor growth and survival in several other cancers, but this is the first confirmation of their role in early-stage lung cancer progression. Further experiments confirmed the expression of aurora kinases in tumors and found that their disruption by inhibitors decreased invasiveness behavior in vitro. Similarly, the use of aurora kinase inhibitors in genetically engineered mice suppressed invasion and improved survival.

This study, combining the research and clinical expertise from Icahn Mount Sinai with Sema4s advanced network modeling methods, is a textbook example of how in silico and experimental technologies can complement one another to accelerate research, said Dr. Powell. We look forward to continuing this collaboration with Sema4 to investigate the therapeutic application of aurora kinase inhibitors in early-stage lung adenocarcinoma further.

The published study is based on technology developed by Mount Sinai faculty. In addition to their roles with Sema4, Drs. Schadt and Zhu remain affiliated with Icahn Mount Sinai as part-time faculty members. Mount Sinai and Mount Sinai faculty, including Drs. Schadt and Zhu, have a financial interest in Sema4. Mount Sinai also has representation on the Sema4 Board of Directors.

About Sema4Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visitsema4.com and connect with Sema4 onTwitter, LinkedIn, FacebookandYouTube.

About the Mount Sinai Health SystemThe Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked onU.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Reports Best Childrens Hospitals among the countrys best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. NewsweeksThe Worlds Best Smart Hospitals ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visithttps://www.mountsinai.orgor find Mount Sinai onFacebook,TwitterandYouTube.

Sema4 Media ContactRadley Mossradley.moss@sema4.com

Visit link:
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy - GlobeNewswire

Posted in Integrative Medicine | Comments Off on Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy – GlobeNewswire

Page 495«..1020..494495496497..500510..»